These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38385713)

  • 1. Cost-effective 3D lung tissue spheroid as a model for SARS-CoV-2 infection and drug screening.
    Miranda GASC; Corrêa IA; Amorim ÉA; Caldas LA; Carneiro FÁ; da Costa LJ; Granjeiro JM; Tanuri A; de Souza W; Baptista LS
    Artif Organs; 2024 Jul; 48(7):723-733. PubMed ID: 38385713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spheroids and organoids as humanized 3D scaffold-free engineered tissues for SARS-CoV-2 viral infection and drug screening.
    Kronemberger GS; Carneiro FA; Rezende DF; Baptista LS
    Artif Organs; 2021 Jun; 45(6):548-558. PubMed ID: 33264436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Kidney Spheroids and Monolayers Provide Insights into SARS-CoV-2 Renal Interactions.
    Omer D; Pleniceanu O; Gnatek Y; Namestnikov M; Cohen-Zontag O; Goldberg S; Friedman YE; Friedman N; Mandelboim M; Vitner EB; Achdout H; Avraham R; Zahavy E; Israely T; Mayan H; Dekel B
    J Am Soc Nephrol; 2021 Sep; 32(9):2242-2254. PubMed ID: 34112705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening.
    Ebisudani T; Sugimoto S; Haga K; Mitsuishi A; Takai-Todaka R; Fujii M; Toshimitsu K; Hamamoto J; Sugihara K; Hishida T; Asamura H; Fukunaga K; Yasuda H; Katayama K; Sato T
    Cell Rep; 2021 Jun; 35(10):109218. PubMed ID: 34038715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery.
    Mulay A; Konda B; Garcia G; Yao C; Beil S; Villalba JM; Koziol C; Sen C; Purkayastha A; Kolls JK; Pociask DA; Pessina P; de Aja JS; Garcia-de-Alba C; Kim CF; Gomperts B; Arumugaswami V; Stripp BR
    Cell Rep; 2021 May; 35(5):109055. PubMed ID: 33905739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.
    Grau-Expósito J; Perea D; Suppi M; Massana N; Vergara A; Soler MJ; Trinite B; Blanco J; García-Pérez J; Alcamí J; Serrano-Mollar A; Rosado J; Falcó V; Genescà M; Buzon MJ
    PLoS Pathog; 2022 Jan; 18(1):e1010171. PubMed ID: 35025963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.
    Han Y; Duan X; Yang L; Nilsson-Payant BE; Wang P; Duan F; Tang X; Yaron TM; Zhang T; Uhl S; Bram Y; Richardson C; Zhu J; Zhao Z; Redmond D; Houghton S; Nguyen DT; Xu D; Wang X; Jessurun J; Borczuk A; Huang Y; Johnson JL; Liu Y; Xiang J; Wang H; Cantley LC; tenOever BR; Ho DD; Pan FC; Evans T; Chen HJ; Schwartz RE; Chen S
    Nature; 2021 Jan; 589(7841):270-275. PubMed ID: 33116299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Three-Dimensional
    Swaminathan S; Cranston AN; Clyne AM
    Tissue Eng Part C Methods; 2019 Oct; 25(10):609-618. PubMed ID: 31441384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
    Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
    J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D culture models to study SARS-CoV-2 infectivity and antiviral candidates: From spheroids to bioprinting.
    de Melo BAG; Benincasa JC; Cruz EM; Maricato JT; Porcionatto MA
    Biomed J; 2021 Mar; 44(1):31-42. PubMed ID: 33602633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
    Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection.
    Sohn SY; Hearing J; Mugavero J; Kirillov V; Gorbunova E; Helminiak L; Mishra S; Mackow E; Hearing P; Reich NC; Kim HK
    mBio; 2021 Dec; 12(6):e0275621. PubMed ID: 34724828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription-based drug repurposing for COVID-19.
    Killick R; Ballard C; Doherty P; Williams G
    Virus Res; 2020 Dec; 290():198176. PubMed ID: 32987033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
    Sallenave JM; Guillot L
    Front Immunol; 2020; 11():1229. PubMed ID: 32574272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection.
    Pei R; Feng J; Zhang Y; Sun H; Li L; Yang X; He J; Xiao S; Xiong J; Lin Y; Wen K; Zhou H; Chen J; Rong Z; Chen X
    Protein Cell; 2021 Sep; 12(9):717-733. PubMed ID: 33314005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
    Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
    Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
    Wahl A; Gralinski LE; Johnson CE; Yao W; Kovarova M; Dinnon KH; Liu H; Madden VJ; Krzystek HM; De C; White KK; Gully K; Schäfer A; Zaman T; Leist SR; Grant PO; Bluemling GR; Kolykhalov AA; Natchus MG; Askin FB; Painter G; Browne EP; Jones CD; Pickles RJ; Baric RS; Garcia JV
    Nature; 2021 Mar; 591(7850):451-457. PubMed ID: 33561864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A SCID mouse-human lung xenograft model of SARS-CoV-2 infection.
    Fu W; Wang W; Yuan L; Lin Y; Huang X; Chen R; Cai M; Liu C; Chen L; Zhou M; Wu K; Zhao H; Pan D; Ma J; Hong J; Zhai B; Zhang Y; Kong Z; Wang Y; Chen Y; Yuan Q; Zhu H; Cheng T; Guan Y; Xia N
    Theranostics; 2021; 11(13):6607-6615. PubMed ID: 33995679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.